|1.||Koch, Cameron J: 7 articles (11/2010 - 01/2003)|
|2.||Evans, Sydney M: 7 articles (11/2010 - 01/2003)|
|3.||Evans, S M: 6 articles (02/2003 - 02/2000)|
|4.||Koch, C J: 6 articles (02/2003 - 02/2000)|
|5.||Kumar, Piyush: 5 articles (07/2015 - 11/2002)|
|6.||Hahn, Stephen M: 5 articles (11/2010 - 12/2004)|
|7.||Hart, Charles P: 4 articles (01/2015 - 04/2008)|
|8.||Wiebe, Leonard I: 4 articles (10/2012 - 11/2002)|
|9.||Jenkins, W T: 4 articles (02/2003 - 02/2000)|
|10.||Matteucci, Mark D: 3 articles (01/2015 - 02/2012)|
10/01/2008 - "The study revealed that complex under investigation has features similar to other 2-nitroimidazole complexes so far as the retention of injected activity in tumor is concerned."
03/01/2013 - "Our in vitro findings suggest that PRC might be a promising new 2-nitroimidazole for improving radiation therapy of hypoxic tumors in vivo."
11/01/2012 - "The data should be useful to evaluate the novel 2-nitroimidazole derivatives as potential PET tumor imaging agents."
05/01/2011 - "Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging."
02/01/2010 - "Biodistribution of the radiolabelled 2-nitroimidazole conjugates was carried out in EMT6 tumor-bearing mice. "
09/01/1998 - "2-Nitroimidazole hypoxia markers show considerable promise for clinical use in diagnosing hypoxia and their use could allow rational application of hypoxia-related therapies to those patients most likely to benefit from them."
04/01/2011 - "In this study, BnAO, a ligand that had been labeled with (99m)Tc-pertechnetate for hypoxia imaging, was conjugated with 2-nitroimidazole to give 3,3,10,10-tetramethyl-1-(2-nitro-1H-imidazo-1-y1)-4,9-diazadodecane-2,11- dionedioxime (BnAO-NI) as a potential ligand for hypoxia detection. "
05/01/2015 - "[(18)F]HX4 is a 2-nitroimidazole based investigational radiotracer for imaging hypoxia. "
03/21/2012 - "GPU-167 comprises a tricarbocyanine dye as an NIR fluorophore and two 2-nitroimidazole moieties as exogenous hypoxia markers that undergo bioreductive activation and then selective entrapment in hypoxic cells. "
05/01/2008 - "NLNQ-1, which combines a naphthoquinone (with a relatively high one electron reduction potential) with a 2-nitroimidazole (with a relatively low one electron reduction potential), could perform as a more potent hypoxia-selective cytotoxin and radiosensitizer. "
02/01/1995 - "NNB shows greater hypoxic selectivity than the alkylating 2-nitroimidazole RB 6145 against AA8 cells and is active in combination with radiation when administered in multiple doses against the MDAH-MCa-4 mouse mammary carcinoma."
12/11/1991 - "Exposure of HT-29 colon carcinoma cells to 1-methyl-2-nitrosoimidazole (INO), a reductive metabolite of a model 2-nitroimidazole, induced concentration-dependent DNA damage detectable by conventional alkaline (single-strand breaks) and neutral (double-strand breaks) filter elution techniques. "
02/01/2001 - "Marking hypoxia in rat prostate carcinomas with beta-D-[125I]azomycin galactopyranoside and."
01/01/1984 - "The radiosensitizing efficacy of SR-2508, a new 2-nitroimidazole, which is less neurotoxic than misonidazole (MISO) was studied using transplantable mammary carcinoma of C3H/He mice. "
05/01/2002 - "The biochemical effects of the 2-nitroimidazole hypoxic cell radiosensitizers KIN-804, KIN-806, and their analogues KIN-844 and TX-1877 on brain acetylcholinesterase (AChE) and hepatic free radical scavenging systems, such as reduced glutathione (GSH) and glucose-6-phosphate dehydrogenase (G-6-PDH) levels, and hepatic antioxidants, such as superoxide dismutase (SOD) and catalase, were evaluated in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. "
11/01/1989 - "The influence of altered tumour oxygenation on the responses to radiation and/or bioreductive 2-nitroimidazole compounds was studied in a well differentiated, human, colon adenocarcinoma (MAWI), grown as a subcutaneous xenograft in nude mice. "
01/01/1989 - "Misonidazole, a clinically-effective 2-nitroimidazole hypoxic cell radiation sensitizer, and 12 4-nitro-5-sulfonatoimidazoles were tested in cultured human SW1116 colorectal adenocarcinoma cells for radiosensitizing efficiency. "
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
|2.||Heterologous Transplantation (Xenotransplantation)